News:

Company Selected as a 2020 San Diego Cool Company Industry Veteran Ken Wilke Joins Team to Lead Strategy and Operations for ORP100S Development SAN DIEGO, CA – May 28, 2020 – OrPro Therapeutics announced today that it is expanding its patented technology platform for treatment of acute and chronic airway diseases, including cystic fibrosis (CF), […]

– Demonstrates Restoration of Mucus Transportability – SAN DIEGO, October 28, 2016 — OrPro Therapeutics, Inc., and its research collaborators at the University of Alabama at Birmingham (UAB) today presented promising new non-clinical human subject data on the efficacy of OrPro’s inhaled mucus-normalizing drug Theradux™ (modified human thioredoxin-1) during a poster session at the North […]

– Broad claims extend protection to 2034 – – In vivo safety and mechanism-based proof-of-concept data presented at key conferences – SAN DIEGO, October 27, 2015 — OrPro Therapeutics, Inc. announced today that the US Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,168,290 covering the ability of Theradux™ (recombinant modified human thioredoxin-1) […]

SAN DIEGO, Oct. 9, 2014 /PRNewswire/ — OrPro Therapeutics, Inc., a pre-clinical stage biopharmaceutical company, announced that it will present data on the development of its inhaled treatment for cystic fibrosis (CF) at the 28thAnnual North American Cystic Fibrosis Conference, October 9 – 11 in Atlanta. CF is an inherited genetic disease that affects approximately 80,000 people worldwide. OrPro’s lead compound, […]

July 31, 2012, SAN DIEGO -­‐-­‐ OrPro Therapeutics Inc. today announced that the company has been awarded a National Heart, Lung and Blood Institute Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The grant enables OrPro to advance development of its lead product, ORP-­‐ 100, for the treatment of cystic […]